source
- MapLight shifts focus to schizophrenia drug after mixed Phase 2 results, raises $150 millionMapLight Therapeutics reported mixed outcomes from its Phase 2 Zephyr trial of the muscarinic agonist ML-007C-MA. A twice‑daily dose achieved the study’s primary endpoint with notable reductions in…
- Biotech initiatives pick up as more regions race to become hubsNew government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.BioPharma Dive · 23m ago↗ source